On Friday, an EMA committee recommended extending the use of Eli Lilly's type 2 diabetes drug, Mounjaro, to children as young ...

Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Dec 12 (Reuters) - The European Medicines ‌Agency's ​committee on Friday ‌recommended extending the use of Eli Lilly's ...

Mounjaro and Pfizer’s ($PFE) cancer drugs were added to China’s state-run health insurance scheme, according to the country’s ...

The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...

Eli Lilly's Mounjaro drug to be added to China's health insurance scheme for type 2 diabetes patients, potentially impacting ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...